Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.

Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C.

Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90.

PMID:
8997599
2.

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.

J Pharmacol Exp Ther. 1996 Jan;276(1):150-60.

PMID:
8558425
4.

Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.

Gleason SD, Witkin JM.

Behav Pharmacol. 2004 Feb;15(1):85-9.

PMID:
15075630
5.

Effects of selective dopamine D1- and D2-type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT.

Mattingly BA, Himmler C, Bonta T, Rice LL.

Psychopharmacology (Berl). 1998 Dec;140(4):387-97.

PMID:
9888612
6.
7.

The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.

Wirtshafter D, Osborn CV.

Eur J Pharmacol. 2005 Dec 28;528(1-3):88-94. Epub 2005 Dec 1.

PMID:
16324697
8.
10.

In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.

Fenu S, Espa E, Pisanu A, Di Chiara G.

Eur J Pharmacol. 2016 Oct 5;788:183-191. doi: 10.1016/j.ejphar.2016.06.035. Epub 2016 Jun 22.

PMID:
27343381
11.

Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.

Johnson KB, Criswell HE, Jensen KF, Simson PE, Mueller RA, Breese GR.

J Pharmacol Exp Ther. 1992 Aug;262(2):855-65.

PMID:
1354257
12.
13.

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.

Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD.

Psychopharmacology (Berl). 1999 Feb;142(1):51-60.

PMID:
10102782
14.

Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.

Michaelides MR, Hong Y, DiDomenico S Jr, Bayburt EK, Asin KE, Britton DR, Lin CW, Shiosaki K.

J Med Chem. 1997 May 23;40(11):1585-99.

PMID:
9171869
15.
16.

D2 and D1 dopaminergic activity of 7-OH-DPAT.

Sethy VH, Ellerbrock BR, Fici GJ, Wu H.

Brain Res. 1996 Sep 9;733(1):41-5.

PMID:
8891246
17.

Phencyclidine supersensitivity in rats with neonatal dopamine loss.

Moy SS, Breese GR.

Psychopharmacology (Berl). 2002 May;161(3):255-62. Epub 2002 Apr 5.

PMID:
12021828
18.

Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.

Moro H, Sato H, Ida I, Oshima A, Sakurai N, Shihara N, Horikawa Y, Mikuni M.

Pharmacol Biochem Behav. 2007 May;87(1):56-64. Epub 2007 Apr 6.

PMID:
17499349
19.

Supplemental Content

Support Center